On March 14, we presented, in collaboration with ECET, the webinar: The challenges within Epilepsy Trials in EuropeDuring this webinar, guest speakers Prof. Jacqueline French, Prof. Alexis Arzimanoglou and Prof. Eugen Trinka discussed:–...
During this webinar, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requi...
During the 5th Global NASH Congress in London, Our Chief Scientific Officer Prof. Dr. D.E. Grobbee was one of the speakers and presented: Getting GRIP on NASH; Implementation of an International Clinical Screening Program.During this presentat...
In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...
Hosted by: Julius Clinical.Speakers:Pieter van Bokhoven | CSO| IAO Amsterdam Neuroscience AUMC Jort Vijverberg | Neurologist | Amsterdam Neuroscience AUMCTopics that are discussed during this webinar:All major trends in Alzh...
Topics that has been discussed:The Impact of NAFLD/NASH What is being done to tackle NAFLD/NASH globally and nationally What still needs to be done in the fight against NAFLD/NASH How can you/your country advance the battle against ...
Genome-wide association studies have uncovered robust and reproducible associations between several genetic variations and the natural history of NAFLD. During this webinar, Professor Eric Trépo reviewed these findings that have provided compelli...
We presented the webinar COVID-19 lessons from pandemic to endemic. During this webinar Prof. Jerome H. Kim, Director General of the International Vaccine Institute (IVI), discussed:- Pandemic preparedness – lessons learned - Clinical Devel...
Together with our partner TRICALS, we presented the webinar: Efficient Patient Identification in ALS Clinical Trials; Leveraging the Concept of Fast and Slow Progressors.During this webinar, Prof. Dr. L.H. van den Berg and R.P.A van Eijk talke...
During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (p...
"*" indicates required fields
"*" indicates required fields
